.Pharmacolibrary.Drugs.ATC.A.A04AD12 .Pharmacolibrary.Drugs.ATC.A.A04AD12| name: | Aprepitant |
| ATC code: | A04AD12 | route: | oral |
| n-compartments | 2 |
Aprepitant is a selective neurokinin-1 (NK1) receptor antagonist used for the prevention of acute and delayed nausea and vomiting associated with chemotherapy and for the prevention of postoperative nausea and vomiting. It is an approved, orally administered antiemetic drug.
Pharmacokinetic parameters reported in healthy adult subjects after oral administration.
Nakade, S, et al., & Miyata, Y (2008). Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting. Cancer chemotherapy and pharmacology 63(1) 75–83. DOI:10.1007/s00280-008-0713-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/18317761
Nijstad, AL, et al., & Huitema, ADR (2023). A simple extemporaneous oral suspension of aprepitant yields sufficient pharmacokinetic exposure in children. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 29(4) 899–904. DOI:10.1177/10781552221089243 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35377726
Yang, MJ, et al., & Li, XN (2020). Comparison of Pharmacokinetics of Aprepitant in Healthy Chinese and Caucasian Subjects. Drug design, development and therapy 14 1219–1226. DOI:10.2147/DDDT.S243924 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32273684